查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014538

纤维蛋白胶市场：全球市场按产品类型、配方类型、技术、应用和最终用户分類的预测——2026-2032年

Fibrin Sealant Market by Product Type, Formulation Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，纤维蛋白胶市场价值将达到 5.1003 亿美元，到 2026 年将成长至 5.8459 亿美元，到 2032 年将达到 13.1632 亿美元，年复合成长率为 14.50%。

主要市场统计数据
基准年 2025 510,030,000 美元
预计年份：2026年 5.8459亿美元
预测年份 2032 1,316,320,000 美元
复合年增长率 (%) 14.50%

对纤维蛋白胶进行简明策略概述：从临床进展、监管趋势和影响应用趋势的商业性因素等方面说明。

本执行摘要概述了纤维蛋白胶的发展趋势，并将该技术定位于外科创新与复杂供应链的交汇点。近年来，药物化学、给药技术和临床证据的进步，使纤维蛋白胶从辅助产品跃升为影响手术效率、止血效果和手术全期工作流程的策略工具。因此，临床、商业和采购部门的相关人员正在重新评估产品选择、手术室规程和采购实践，使其既符合临床目标，又符合组织限制。

纤维蛋白胶领域正在发生新的变革，这是由给药方法、临床结果、报销趋势和引入模式的创新所驱动的。

纤维蛋白胶的市场格局正经历着变革性的转变，这主要归因于技术、临床实践和商业化等多方面因素的共同作用。给药方式的创新拓展了密封剂的实际应用范围，而配方的不断改进则提高了操作便利性，并增强了其与各种外科手术流程的兼容性。这些技术进步的动力在于不断增长的临床数据，这些数据更清晰地展现了每种手术的益处，从而促使临床医生对符合其偏好的专用产品形式的需求日益增长。

评估 2025 年美国关税对纤维蛋白胶采购、供应链韧性、筹资策略和临床实践准入的累积影响。

美国计划于2025年实施的关税措施将使纤维蛋白胶的供应链和医院采购惯例更加复杂。关税调整将直接影响成品和关键原材料的到货成本，进而可能影响製造商和分销合作伙伴的采购决策。在许多情况下，供应商可能会重新评估其总服务成本并优化製造地，修改原材料供应合同，或调整定价策略，以在确保利润率的同时维持服务水准。

有助于制定策略的细分洞察，提取产品类型、应用子细分、最终用户环境、配方选择和技术差异。

细分市场提供了必要的分析框架，可以将产品属性转化为临床和商业性选择。基于产品类型的液体配方、贴片式基质和喷雾给药系统之间的差异，决定了密封剂如何融入外科手术、储存和处理流程以及临床医生的偏好。液体配方通常便于在狭小空间内进行精确涂抹；贴片可在止血或组织密封需要大面积接触时提供结构覆盖；而喷雾系统则可快速均匀地应用于较大面积。

区域洞察，探索美洲、欧洲、中东和非洲以及亚太地区的需求驱动因素、报销框架、监管细微差别以及临床实践的差异。

区域趋势对监管路径、支付方互动以及临床医生的诊疗模式均有显着影响，因此，从区域观点出发制定有效策略至关重要。在美洲，医疗保健采购者往往优先考虑临床证据和总体拥有成本 (TCO) 的结合，而供应商则经常进行价值论证计画和上市后监测，以支援产品推广应用。该地区的采购週期涉及与医院集团的复杂谈判，并可能受到国家报销框架和医疗服务提供者处方集的影响，因此，制定符合区域实际情况的商业性策略至关重要。

公司对纤维蛋白胶的产品系列、创新轨迹、商业化策略、竞争定位和市场推出的洞察。

企业层面的行动反映了其在创新投资方向、商业模式建构以及伙伴关係关係选择方面的策略考量。注重产品组合广度的企业通常会提供多种产品形式，例如液体、贴片和喷雾剂，并将每种产品与明确的临床应用案例相结合，以促进临床医生的采纳。另一方面，专注于平台深度的企业则会不断改进核心技术，以拓展适应症并提升营运体验。这种做法或许能够赢得临床医师的强力支持，但在需要多种治疗方式的环境中，其吸引力可能有限。

为行业领导者提供实用建议，以优化产品开发、增强供应韧性、提高支付方参与度并加快临床医生采用。

产业领导者应采取切实可行的策略步骤，以平衡短期业务永续营运与中期临床和商业性定位。首先，透过采购多元化、提高物流透明度以及协商确保价格稳定和在供应中断期间优先分配的合约条款，增强供应链韧性。其次，使产品开发蓝图与明确的临床挑战保持一致，并优先改善那些能够缩短给药时间、降低製备复杂性以及提高与常见手术流程相容性的方面。

调查方法，包括资料收集方法、一手和二手资讯的整合、检验方案和分析方法。

本研究整合了多种调查方法，以确保其可靠性和有效性。主要调查方法包括对执业外科医生、手术室护理主管、采购负责人和供应链经理进行结构化访谈，以收集关于产品处理、临床权衡和采购限制的第一手观点。这些定性资讯与同行评审的临床文献和指南的系统性回顾进行交叉比对，以检验临床结论并识别特定手术的证据缺口。

简洁的结论整合了策略意义和可操作的后续步骤，旨在为寻求临床影响和商业性价值的相关人员提供协助。

本分析整合了临床、商业、监管和供应链观点，旨在为相关人员提供一致的洞察。证据表明，临床应用越来越倾向于选择能够提高治疗效率和提供可验证疗效的产品，而采购决策则同时受到成本和供应商可靠性的双重影响。不断发展的给药技术和支付方的严格审查，都要求制定一项整合产品创新、提供可靠证据并为临床医生提供切实支持的综合策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：纤维蛋白胶市场：依产品类型划分

  • 液体
  • 修补
  • 喷

第九章：依配方类型分類的纤维蛋白胶市场

  • 预混合料
  • 两件套

第十章：纤维蛋白胶市场：依技术划分

  • 手动应用
  • 喷洒应用

第十一章：纤维蛋白胶市场：依应用领域划分

  • 心血管系统
    • 旁路
    • 阀门维修
  • 牙科
  • 一般外科
    • 腹部
    • 胸部
  • 神经外科
  • 整形外科
    • 关节重组
    • 创伤固定
  • 创伤护理

第十二章：纤维蛋白胶市场：依最终用户划分

  • 门诊手术中心
  • 诊所
  • 医院

第十三章：纤维蛋白胶市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：纤维蛋白胶市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：纤维蛋白胶市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国纤维蛋白胶市场

第十七章：中国纤维蛋白胶市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bayer AG
  • CryoLife, Inc.
  • CSL Behring GmbH
  • Ethicon Inc.
  • FzioMed Inc.
  • Haemacure Corporation
  • Hemarus Therapeutics（India）Pvt. Ltd.
  • Hemostasis LLC
  • Hualan Biological Engineering Inc.
  • Hunan Kelun-Biotech Co., Ltd.
  • Integra LifeSciences Corporation
  • LFB Group
  • Mallinckrodt Pharmaceuticals Holdings Inc.
  • Omrix Biopharmaceuticals Ltd.
  • Omrix Biopharmaceuticals, Inc.
  • Sanofi SA
  • Shanghai Haoyuan Biological Manufacturing Co., Ltd.
  • Shanghai Haoyuan Biological Manufacturing Co., Ltd.
  • Shanghai Hualan Biological Engineering Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Tissuemed Ltd.
Product Code: MRR-4348D129FB3E

The Fibrin Sealant Market was valued at USD 510.03 million in 2025 and is projected to grow to USD 584.59 million in 2026, with a CAGR of 14.50%, reaching USD 1,316.32 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 510.03 million
Estimated Year [2026] USD 584.59 million
Forecast Year [2032] USD 1,316.32 million
CAGR (%) 14.50%

A concise strategic overview of fibrin sealant that contextualizes clinical advances, regulatory dynamics, and commercial levers shaping adoption trends

This executive summary introduces the evolving landscape of fibrin sealants, situating the technology at the intersection of surgical innovation and supply chain sophistication. Over recent years, advancements in formulation chemistry, delivery techniques, and clinical evidence have elevated sealants from adjunctive products to strategic tools that influence procedural efficiency, hemostasis outcomes, and perioperative workflows. As a result, stakeholders across clinical, commercial, and procurement functions are reassessing product selection, operating room protocols, and purchasing practices to align with both clinical objectives and institutional constraints.

The introduction clarifies the fundamental attributes and clinical rationale that underpin fibrin sealant adoption, emphasizing the ways in which product form and delivery method interact with surgical indications and facility capacities. It also frames the broader regulatory and reimbursement backdrop that influences procurement decisions and clinician preferences, including growing emphasis on real-world evidence and value-based care metrics. By grounding readers in these primary themes, the section prepares decision-makers to evaluate tactical choices in product adoption, clinical training, and supplier engagement.

Finally, the introduction outlines the structure of the full analysis and highlights how the subsequent sections interrelate: technology and product innovations inform segmentation and clinical use cases, which in turn interact with regional regulatory environments and recent trade policy developments to shape procurement strategies. This framing ensures readers can move from high-level context to operationally relevant conclusions without losing sight of cross-functional implications

Emerging transformative shifts in the fibrin sealant landscape driven by delivery innovation, clinical outcomes, reimbursement dynamics, and adoption patterns

The landscape for fibrin sealants is experiencing transformative shifts driven by converging forces in technology, clinical practice, and commercialization. Innovations in delivery approaches have expanded the practical settings in which sealants are used, while iterative formulation improvements have increased handling convenience and broadened compatibility with diverse surgical workflows. These technical evolutions are being reinforced by a proliferation of clinical data that more clearly delineates procedure-specific benefits, which in turn is driving demand for specialized product formats aligned to clinician preferences.

Concurrently, payer dynamics and hospital procurement strategies are reshaping commercial realities. Increasing scrutiny on procedural costs, bundled payment models, and outcome-based purchasing means that product differentiation must be substantiated by demonstrable value in efficiency, complication reduction, or length-of-stay improvements. As stakeholders respond, new partnership models and distribution strategies are emerging that emphasize integrated solutions-training, procedural protocols, and post-market evidence collection-rather than singular product transactions.

Moreover, the role of surgeon and OR leadership preferences cannot be overstated; clinician champions often accelerate local adoption when supported by clear clinical data and seamless intraoperative workflows. Taken together, these shifts signal a market that rewards companies and health systems able to synchronize product innovation with evidence generation, reimbursement alignment, and targeted commercialization, thereby moving the field from commodity purchasing toward strategic, evidence-driven procurement

Assessing the cumulative impact of United States tariffs for 2025 on fibrin sealant procurement, supply chain resilience, sourcing strategies, and clinical access

The United States tariff actions scheduled for 2025 introduce a new layer of complexity for fibrin sealant supply chains and hospital procurement practices. Tariff adjustments can directly influence landed costs for finished products and critical inputs, thereby affecting sourcing decisions made by manufacturers and distribution partners. In many cases, suppliers will evaluate the total cost-to-serve and may reoptimize their manufacturing footprints, alter supplier contracts for raw materials, or adjust pricing strategies to preserve margins while maintaining service levels.

For clinical users and procurement teams, the immediate impacts are likely to manifest through changed contract negotiations, potential re-evaluation of supplier multi-sourcing strategies, and a heightened emphasis on inventory planning and contingency buffers. Hospitals and ambulatory centers may respond by prioritizing agreement terms that offer predictable pricing and guaranteed supply, or by exploring alternative products and local sourcing arrangements where feasible. In parallel, manufacturers with diversified production sites or vertically integrated supply chains may be comparatively better positioned to absorb tariff-related cost increases without passing the entire burden to purchasers.

Clinically, any disruptions in product availability could influence procedural scheduling and device selection, particularly in specialty areas where product substitution is operationally burdensome. Therefore, risk mitigation measures such as dual-sourcing, expanded safety stock policies, and enhanced logistics visibility are likely to be central to institutional responses. Overall, the tariff environment underscores the need for both suppliers and buyers to develop adaptive supply chain strategies that reconcile regulatory shifts with the imperative to maintain clinical continuity and cost predictability

Segmentation insights distilling product types, application subsegments, end user settings, formulation options, and technology differences to inform strategy

Segmentation offers the analytical scaffolding required to translate product attributes into clinical and commercial choices. Based on Product Type, differentiation among liquid formulations, patch-based matrices, and spray delivery systems determines how a sealant integrates into operative technique, storage and handling protocols, and clinician preference. Liquid formats typically facilitate precise placement in confined spaces, patch configurations can deliver structural coverage where hemostasis and tissue sealing need broader contact, and spray systems enable rapid, uniform application across larger surfaces.

Based on Application, clinical value is shaped by procedure-specific requirements that range from cardiovascular interventions such as bypass and valve repair to dental and neurosurgical contexts, as well as common general surgery practices including abdominal and thoracic procedures. Orthopedic uses span joint reconstruction and trauma fixation where mechanical stability and hemostasis intersect, while wound care applications emphasize adhesion and healing characteristics in mixed outpatient and inpatient settings. These application distinctions inform training needs, choice of formulation, and intraoperative logistics.

Based on End User, the operational realities of ambulatory surgical centers, outpatient clinics, and hospitals influence product selection, procurement cadence, and inventory management. Formulation Type further stratifies market dynamics: pre mixed preparations offer convenience and reduced setup time, whereas two component kits provide longer shelf stability and flexibility in dosing. Finally, Based on Technology, manual application versus spray application presents trade-offs between precision and speed, and the decision to adopt a particular technology is frequently driven by the interplay of clinical indication, OR throughput goals, and the learning curve for surgical teams. Integrating these segmentation lenses enables stakeholders to align product development, portfolio management, and commercialization strategies with nuanced clinical use cases and facility capabilities

Regional insights exploring demand drivers, reimbursement frameworks, regulatory nuances, and clinical practice variations across Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence regulatory pathways, payer interactions, and clinician practice patterns, so a geography-sensitive view is essential for effective strategy. In the Americas, healthcare purchasers tend to prioritize a combination of clinical evidence and total cost of ownership, and suppliers frequently engage in value demonstration programs and post-market studies to support adoption. Procurement cycles in this region involve complex hospital group negotiations and can be affected by national reimbursement frameworks and institutional formularies, necessitating tailored commercial approaches.

Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where national health technology assessment processes and local hospital procurement policies shape adoption. In several EMEA markets, demonstrating cost-effectiveness through health economic modeling and real-world outcomes is a decisive factor in gaining traction, while markets with constrained resources may favor multi-use or cost-efficient options that align with local supply capabilities. Local regulatory nuance and import considerations can also dictate how suppliers structure distribution and support services.

Asia-Pacific displays rapid clinical adoption in certain urban centers alongside emerging demand in broader regional markets; here, supplier success often depends on navigating diverse regulatory approvals, establishing robust local distribution networks, and supporting clinician education at scale. Across all regions, the ability to adapt training, evidence generation, and supply chain strategies to regional priorities is a key differentiator for organizations seeking sustainable commercial success and clinical impact

Company insights on product portfolios, innovation trajectories, commercialization tactics, competitive positioning, and go-to-market in fibrin sealant

Company-level behavior reflects strategic choices about where to invest in innovation, how to structure commercial models, and which partnerships to pursue. Organizations that emphasize portfolio breadth tend to offer multiple product formats-liquids, patches, sprays-and position each against clear clinical use cases to simplify adoption for clinicians. Others focus on platform depth, iterating on a core technology to expand indications or improve handling, which can create strong clinician loyalty but may limit appeal in settings that demand multiple modalities.

Innovation pipelines are increasingly judged not just on formulation novelty but on how new products reduce procedural complexity, shorten OR time, or lower complication rates. Commercially, firms are experimenting with bundled offerings that combine product supply with surgeon training, intraoperative decision support, and post-market evidence programs aimed at demonstrating downstream economic value. Competitive positioning often hinges on the ability to demonstrate these integrated benefits rather than on single-feature claims.

Partnership strategies, including collaborations with distribution partners, hospital systems, and academic centers, help accelerate adoption and strengthen evidence generation. Companies that proactively engage in clinician education and structured real-world data collection are able to translate clinical insights into clearer purchasing rationales. Finally, go-to-market effectiveness depends on aligning field teams with high-value clinical targets and ensuring that reimbursement and supply chain narratives are integrated into sales conversations to reduce adoption friction

Actionable recommendations for industry leaders to optimize product development, strengthen supply resilience, enhance payer engagement, and boost clinician uptake

Industry leaders should pursue a pragmatic set of strategic actions that balance near-term operational resilience with mid-term clinical and commercial positioning. First, strengthen supply chain resilience by diversifying sourcing, increasing logistics visibility, and negotiating contractual terms that offer price stability and prioritized allocations in the event of disruption. Second, align product development roadmaps with clear clinical pain points; prioritize improvements that shorten application time, reduce preparation complexity, and enhance compatibility with common operative workflows.

Third, invest in evidence generation that explicitly maps product attributes to clinically meaningful outcomes and economic endpoints relevant to payers and hospital procurement committees. Fourth, build differentiated commercialization models that combine product supply with clinician training, outcome monitoring, and procedural toolkits to minimize adoption friction and demonstrate value. Fifth, proactively engage with payers and health system procurement teams to articulate value propositions in terms they prioritize-efficiency gains, complication reduction, or throughput improvements.

Finally, create buyer-focused value propositions for different end user settings, recognizing that ambulatory surgical centers, clinics, and hospitals have distinct priorities. By combining operational safeguards with evidence-based commercial strategies, companies and health systems can accelerate adoption while protecting margins and clinical continuity

Research methodology covering data collection approaches, integration of primary and secondary sources, validation protocols and analytics for rigor

The research integrates multiple methodological strands to ensure robustness and relevance. Primary engagement included structured interviews with practicing surgeons, OR nursing leads, procurement officers, and supply chain managers to capture first-hand perspectives on product handling, clinical trade-offs, and purchasing constraints. These qualitative inputs were cross-referenced with a systematic review of peer-reviewed clinical literature and guideline statements to validate clinical claims and to identify procedure-specific evidence gaps.

On the commercial side, the study analyzed procurement policy trends, public tender templates, and hospital purchasing workflows to understand contract dynamics and decision levers. Validation protocols included triangulation across stakeholder interviews, literature findings, and observed procurement patterns in representative hospitals. Analytical techniques employed included scenario-based supply chain stress testing, qualitative thematic synthesis of clinician interviews, and structured gap analysis to identify unmet needs in product features or evidence generation.

Throughout, care was taken to ensure transparency in source attribution, to document potential biases, and to include sensitivity checks where stakeholder views diverged. The methodology balances depth of clinician insight with breadth of regulatory and procurement context to produce conclusions that are both empirically grounded and operationally actionable

Concise conclusion synthesizing strategic implications and actionable next steps for stakeholders pursuing clinical impact and commercial value

This analysis synthesizes clinical, commercial, regulatory, and supply chain perspectives to present a cohesive set of implications for stakeholders. The evidence indicates that clinical adoption will increasingly favor products that align with procedural efficiency and demonstrable outcome improvements, while procurement decisions will be shaped by both cost considerations and supplier reliability. The confluence of evolving delivery technologies and payer scrutiny calls for integrated strategies that pair product innovation with robust evidence and practical support for clinicians.

Operationally, the priority is to ensure supply continuity and predictable pricing in a changing trade and tariff environment. Institution-level risk management, including inventory policy adjustments and multi-sourced supply agreements, will be essential to mitigate potential disruptions. On the commercial front, firms that can present clear, quantifiable value propositions to payers and hospital procurement teams will have a competitive advantage in capturing long-term institutional contracts.

In conclusion, decision-makers should view fibrin sealant strategy through a multifaceted lens that incorporates product differentiation, evidence generation, supply chain robustness, and region-specific commercialization. By integrating these dimensions into cohesive action plans, stakeholders can translate the research insights into meaningful clinical and economic outcomes

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fibrin Sealant Market, by Product Type

  • 8.1. Liquid
  • 8.2. Patch
  • 8.3. Spray

9. Fibrin Sealant Market, by Formulation Type

  • 9.1. Pre Mixed
  • 9.2. Two Component Kits

10. Fibrin Sealant Market, by Technology

  • 10.1. Manual Application
  • 10.2. Spray Application

11. Fibrin Sealant Market, by Application

  • 11.1. Cardiovascular
    • 11.1.1. Bypass
    • 11.1.2. Valve Repair
  • 11.2. Dental
  • 11.3. General Surgery
    • 11.3.1. Abdominal
    • 11.3.2. Thoracic
  • 11.4. Neurosurgery
  • 11.5. Orthopedic
    • 11.5.1. Joint Reconstruction
    • 11.5.2. Trauma Fixation
  • 11.6. Wound Care

12. Fibrin Sealant Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Fibrin Sealant Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Fibrin Sealant Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Fibrin Sealant Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Fibrin Sealant Market

17. China Fibrin Sealant Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. B. Braun Melsungen AG
  • 18.6. Baxter International Inc.
  • 18.7. Bayer AG
  • 18.8. CryoLife, Inc.
  • 18.9. CSL Behring GmbH
  • 18.10. Ethicon Inc.
  • 18.11. FzioMed Inc.
  • 18.12. Haemacure Corporation
  • 18.13. Hemarus Therapeutics (India) Pvt. Ltd.
  • 18.14. Hemostasis LLC
  • 18.15. Hualan Biological Engineering Inc.
  • 18.16. Hunan Kelun-Biotech Co., Ltd.
  • 18.17. Integra LifeSciences Corporation
  • 18.18. LFB Group
  • 18.19. Mallinckrodt Pharmaceuticals Holdings Inc.
  • 18.20. Omrix Biopharmaceuticals Ltd.
  • 18.21. Omrix Biopharmaceuticals, Inc.
  • 18.22. Sanofi S.A.
  • 18.23. Shanghai Haoyuan Biological Manufacturing Co., Ltd.
  • 18.24. Shanghai Haoyuan Biological Manufacturing Co., Ltd.
  • 18.25. Shanghai Hualan Biological Engineering Inc.
  • 18.26. Shanghai RAAS Blood Products Co., Ltd.
  • 18.27. Shanghai RAAS Blood Products Co., Ltd.
  • 18.28. Tissuemed Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FIBRIN SEALANT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FIBRIN SEALANT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FIBRIN SEALANT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FIBRIN SEALANT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FIBRIN SEALANT MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FIBRIN SEALANT MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FIBRIN SEALANT MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRE MIXED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRE MIXED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FIBRIN SEALANT MARKET SIZE, BY PRE MIXED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TWO COMPONENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TWO COMPONENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TWO COMPONENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FIBRIN SEALANT MARKET SIZE, BY MANUAL APPLICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FIBRIN SEALANT MARKET SIZE, BY MANUAL APPLICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FIBRIN SEALANT MARKET SIZE, BY MANUAL APPLICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY APPLICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY APPLICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FIBRIN SEALANT MARKET SIZE, BY SPRAY APPLICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FIBRIN SEALANT MARKET SIZE, BY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FIBRIN SEALANT MARKET SIZE, BY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FIBRIN SEALANT MARKET SIZE, BY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FIBRIN SEALANT MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FIBRIN SEALANT MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FIBRIN SEALANT MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FIBRIN SEALANT MARKET SIZE, BY DENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FIBRIN SEALANT MARKET SIZE, BY DENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FIBRIN SEALANT MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FIBRIN SEALANT MARKET SIZE, BY THORACIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FIBRIN SEALANT MARKET SIZE, BY THORACIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FIBRIN SEALANT MARKET SIZE, BY THORACIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FIBRIN SEALANT MARKET SIZE, BY NEUROSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FIBRIN SEALANT MARKET SIZE, BY NEUROSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FIBRIN SEALANT MARKET SIZE, BY NEUROSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FIBRIN SEALANT MARKET SIZE, BY JOINT RECONSTRUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FIBRIN SEALANT MARKET SIZE, BY JOINT RECONSTRUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FIBRIN SEALANT MARKET SIZE, BY JOINT RECONSTRUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TRAUMA FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TRAUMA FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FIBRIN SEALANT MARKET SIZE, BY TRAUMA FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FIBRIN SEALANT MARKET SIZE, BY WOUND CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FIBRIN SEALANT MARKET SIZE, BY WOUND CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FIBRIN SEALANT MARKET SIZE, BY WOUND CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FIBRIN SEALANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FIBRIN SEALANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FIBRIN SEALANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FIBRIN SEALANT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FIBRIN SEALANT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FIBRIN SEALANT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FIBRIN SEALANT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FIBRIN SEALANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS FIBRIN SEALANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL FIBRIN SEALANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 165. GCC FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 167. GCC FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 192. G7 FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 194. G7 FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 201. NATO FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 203. NATO FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL FIBRIN SEALANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA FIBRIN SEALANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA FIBRIN SEALANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA FIBRIN SEALANT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA FIBRIN SEALANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA FIBRIN SEALANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA FIBRIN SEALANT MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA FIBRIN SEALANT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA FIBRIN SEALANT MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA FIBRIN SEALANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)